A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our primary product candidate, LYR-210, is a bioabsorbable nasal insert designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. The drug embedded within LYR-210 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 600K | - | - | - | - |
| Net Income | -33M | -93M | -63M | -55M | -44M |
| EPS | $-22.85 | $-71.50 | $-63.00 | $-91.50 | $-167.50 |
| Free Cash Flow | 0 | -72M | -64M | -44M | -29M |
| ROIC | -63.8% | -656.5% | -70.1% | -68.5% | -100.4% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 4.72 | 0.59 | 0.36 | 0.60 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -35M | -96M | -67M | -56M | -44M |
| Operating Margin | -5885.3% | - | - | - | - |
| ROE | 0.0% | -185.0% | -70.1% | -68.5% | -126.8% |
| Shares Outstanding | 2M | 1M | 1M | 1M | 1M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | N/A | 600K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 30M | 39M | 48M | 44M | 20M |
| SG&A | 14M | 18M | 19M | 19M | 13M |
| EBIT | -44M | -56M | -67M | -96M | -35M |
| Op. Margin | N/A | N/A | N/A | N/A | -5885.3% |
| Net Income | -44M | -55M | -63M | -93M | -33M |
| Net Margin | N/A | N/A | N/A | N/A | -5491.2% |
| Non-Recurring | 0 | 0 | 0 | 13M | 2.9M |
| Returns on Capital | |||||
| ROIC | -100.4% | -68.5% | -70.1% | N/M | -63.8% |
| ROE | -126.8% | -68.5% | -70.1% | -185.0% | 0.0% |
| ROA | -79.3% | -50.3% | -44.0% | -89.4% | -75.4% |
| Cash Flow | |||||
| Op. Cash Flow | -26M | -43M | -63M | -70M | -34M |
| Free Cash Flow | -29M | -44M | -64M | -72M | 0 |
| Owner Earnings | -30M | -50M | -69M | -77M | -38M |
| CapEx | 3.4M | 164K | 1.0M | 2.3M | 0 |
| Maint. CapEx | 1.0M | 1.1M | 278K | 471K | 510K |
| Growth CapEx | 2.4M | 0 | 769K | 1.9M | 0 |
| D&A | 1.0M | 1.1M | 278K | 471K | 510K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.8M | 5.4M | 5.9M | 6.7M | 3.7M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -44M |
| Cash & Equiv. | 46M | 33M | 22M | 41M | 44M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.60 | 0.36 | 0.59 | 4.72 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | 34M | 81M | 89M | 12M | -4.3M |
| Total Assets | 55M | 110M | 143M | 66M | 44M |
| Total Liabilities | 21M | 29M | 53M | 55M | 48M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -193M | -249M | -311M | -405M | -427M |
| Working Capital | 30M | 86M | 85M | 30M | 14M |
| Current Assets | 48M | 101M | 105M | 43M | 23M |
| Current Liabilities | 18M | 14M | 20M | 13M | 9.5M |
| Per Share Data | |||||
| EPS | -167.50 | -91.50 | -63.00 | -71.50 | -22.85 |
| Owner EPS | -46.48 | -82.60 | -69.82 | -59.07 | -21.62 |
| Book Value | 53.91 | 133.67 | 89.88 | 8.87 | -2.44 |
| Cash Flow/Share | -40.56 | -71.81 | -63.63 | -53.58 | -18.28 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.6M | 0.6M | 1.0M | 1.3M | 1.8M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.6 | 1.2 | 2.8 | 1.1 | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 1.9 |
| FCF Yield | -53.3% | -44.1% | -26.0% | -579.7% | N/A |
| Market Cap | 55M | 99M | 247M | 12M | 1.2M |
| Avg. Price | 447.36 | 246.81 | 155.47 | 100.64 | 0.65 |
| Year-End Price | 211.00 | 163.50 | 248.50 | 9.55 | 0.65 |
Lyra Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Lyra Therapeutics, Inc. (LYRA) has a 5-year average return on invested capital (ROIC) of -79.7%. This is below average and may indicate limited pricing power.
Lyra Therapeutics, Inc. (LYRA) has a market capitalization of $1M. It is classified as a small-cap stock.
Lyra Therapeutics, Inc. (LYRA) does not currently pay a regular dividend.
Lyra Therapeutics, Inc. (LYRA) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Lyra Therapeutics, Inc. (LYRA) generated $-72 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lyra Therapeutics, Inc. (LYRA) has a debt-to-equity ratio of 4.72. This indicates higher leverage, which may increase financial risk.
Lyra Therapeutics, Inc. (LYRA) reported earnings per share (EPS) of $-71.50 in its most recent fiscal year.
Lyra Therapeutics, Inc. (LYRA) has a return on equity (ROE) of -185.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Lyra Therapeutics, Inc. (LYRA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lyra Therapeutics, Inc. (LYRA) has a book value per share of $8.87, based on its most recent annual SEC filing.